CoChat

The Immunology of Hormone Receptor Positive Breast Cancer

Open access
Goldberg, Jonathan, Pastorello, Ricardo G., Vallius, Tuulia, Davis, Janae, Cui, Yvonne Xiaoyong, Agudo, Judith, Waks, Adrienne G., Keenan, Tanya, McAllister, Sandra S., Tolaney, Sara M., Mittendorf, Elizabeth A., Guerriero, Jennifer L. · 2021 · Frontiers in Immunology
Cited by 171

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Immune checkpoint blockade (ICB) has revolutionized the treatment of cancer patients. The main focus of ICB has been on reinvigorating the adaptive immune response, namely, activating cytotoxic T cells. ICB has demonstrated only modest benefit against advanced breast cancer, as breast tumors typically establish an immune suppressive tumor microenvironment (TME). Triple-negative breast cancer (TNBC) is associated with infiltration of tumor infiltrating lymphocytes (TILs) and patients with TNBC have shown clinical responses to ICB. In contrast, hormone receptor positive (HR+) breast cancer is characterized by low TIL infiltration and minimal response to ICB. Here we review how HR+ breast tumors establish a TME devoid of TILs, have low HLA class I expression, and recruit immune cells, other than T cells, which impact response to therapy. In addition, we review emerging technologies that have been employed to characterize components of the TME to reveal that tumor associated macrophages (TAMs) are abundant in HR+ cancer, are highly immune-suppressive, associated with tumor progression, chemotherapy and ICB-resistance, metastasis and poor survival. We reveal novel therapeutic targets and possible combinations with ICB to enhance anti-tumor immune responses, which may have great potential in HR+ breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2021.674192

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Metadata

Authors
Goldberg, J., Pastorello, R. G., Vallius, T., Davis, J., Cui, Y. X., Agudo, J., Waks, A. G., Keenan, T., McAllister, S. S., Tolaney, S. M., Mittendorf, E. A., & Guerriero, J. L.
Venue
Frontiers in Immunology
Published
2021-05-11
Volume
12
Pages
674192-674192
ISSN
1664-3224 (ISSN-L)
OpenAlex
W3163154187
Cited by
171
References
40
FWCI
8.81
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Immunology of Hormone Receptor Positive Breast Cancer. https://app.cochat.ai/papers/10.3389/fimmu.2021.674192
The paper
Goldberg, J., Pastorello, R. G., Vallius, T., Davis, J., Cui, Y. X., Agudo, J., Waks, A. G., Keenan, T., McAllister, S. S., Tolaney, S. M., Mittendorf, E. A., & Guerriero, J. L. (2021). The Immunology of Hormone Receptor Positive Breast Cancer. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2021.674192

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.